<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137564</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-089</org_study_id>
    <secondary_id>NCI-2014-00638</secondary_id>
    <secondary_id>AMC-089</secondary_id>
    <secondary_id>AMC-089</secondary_id>
    <secondary_id>U01CA121947</secondary_id>
    <nct_id>NCT02137564</nct_id>
  </id_info>
  <brief_title>Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma</brief_title>
  <official_title>A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients With AIDS-Associated Kaposi Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effects, good and bad, of gamma secretase inhibitor
      PF-03084014 and to see how well it works in treating patients with acquired immune deficiency
      virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the
      growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink
      the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the tolerance and clinical response of Kaposi sarcoma (KS) tumors to PF-03084014
      (gamma secretase inhibitor PF-03084014) with assessments of partial response (PR) and
      complete response (CR).

      SECONDARY OBJECTIVES:

      I. Assess the effect of PF-03084014 on human immunodeficiency virus (HIV) viral load in
      plasma and the effect of PF-03084014 on cluster of differentiation (CD)4+ cell number.

      II. Assess the effect of PF-030840414 in peripheral blood mononuclear cells (PBMCs) and
      tumors on Kaposi's sarcoma-associated herpesvirus (KSHV) latent and lytic gene expression.

      III. Assess effects of PF-03084014 on activation of Notch target genes including
      tumor-associated endothelial-mesenchymal transition and cell proliferation markers.

      IV. Assess effects of trough PF-03084014 drug levels on clinical response and toxicity.

      OUTLINE:

      Patients receive gamma secretase inhibitor PF-03084014 orally (PO) twice daily (BID) on days
      1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease
      progression or unacceptable toxicity. Patients with PR, CR, or stable disease (SD) at the end
      of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in
      the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Drug supply unavailable
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical response (PR and CR)</measure>
    <time_frame>Up to 28 days after completion of study treatment</time_frame>
    <description>The results of tumor evaluations will be tabulated. Binomial probabilities and their 95% confidence intervals will be used to estimate the response rates (i.e., overall response rate, partial response rate, complete response rate).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)</measure>
    <time_frame>Up to 28 days after completion of study treatment</time_frame>
    <description>The results of the safety evaluation will be tabulated. The frequency of adverse events (AEs) and their severity will be tabulated to evaluated tolerance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of HIV virus load in plasma</measure>
    <time_frame>Up to 168 days</time_frame>
    <description>The log10 of the level measured at the end of therapy and the log10 of the level obtained at baseline will be calculated for each patient. Descriptive statistics (e.g., mean, standard deviation, minimum and maximum) will be calculated. If sufficient data are available, a paired t-test will be used to test the log10 virus load difference between the end of therapy and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ cell number</measure>
    <time_frame>Up to day 168 days</time_frame>
    <description>The log10 of the level measured at day 22, at the end of therapy, and baseline will be calculated for each patient. Descriptive statistics (e.g., mean, standard deviation, minimum and maximum) will be calculated. If sufficient data are available, a paired t-test will be used to test the log10 CD4+ cell number difference between the end of therapy and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression in tumor samples measured via reverse transcriptase polymerase chain reaction (RT-PCR)</measure>
    <time_frame>Baseline to up to day 8</time_frame>
    <description>Latent and lytic gene expression values will be computed compared to housekeeping genes (e.g. glyceraldehyde-3-phosphate dehydrogenase [GAPDH]), and the ratio of values for each gene at day 8 compared to that at baseline computed for each patient. The median and range will be determined for these ratios. Wilcoxon signed rank test will be used to determine if the ratio is significantly different from 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of Notch target genes in tumor samples, measured via RT-PCR</measure>
    <time_frame>Baseline to up to day 8</time_frame>
    <description>Levels of expression of each gene at baseline and day 8 will be computed compared to housekeeping genes (e.g. GAPDH), and the ratio of values for each gene at day 8 compared to that at baseline computed for each patient. The median and range will be determined for these ratios. Wilcoxon signed rank test will be used to determine if the ratio is significantly different from 1.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough gamma secretase inhibitor PF-03084014 drug levels</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Analysis of variance will be used to assess the relationship between trough drug levels and the likelihood of response, the response duration, and time to progression. Analysis of variance will be used to assess the relationship between trough drug levels and the likelihood of grade 3 or higher toxicity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>AIDS-related Kaposi Sarcoma</condition>
  <condition>HIV Infection</condition>
  <condition>Recurrent Kaposi Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (gamma secretase inhibitor PF-03084014)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gamma secretase inhibitor PF-03084014</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (gamma secretase inhibitor PF-03084014)</arm_group_label>
    <other_name>PF-03084014</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gamma secretase inhibitor PF-03084014)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (gamma secretase inhibitor PF-03084014)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven KS involving skin, with or without visceral involvement, either newly
             diagnosed or refractory to or intolerant of one or more prior therapies

          -  Participants must have cutaneous lesion(s) amenable to four total biopsies (either
             four lesions &gt; 4 mm or one large lesion measuring 20 mm that can undergo serial
             biopsy) and at least five additional lesions measurable for assessment with no
             improvement over the past month

          -  There should be no evidence for improvement in KS in the 3 months prior to study
             entry, unless there is also evidence for progression of KS in the 4 weeks immediately
             prior to study entry

          -  Serologic documentation of HIV infection by any of the Food and Drug Administration
             (FDA)-approved tests

          -  Karnofsky performance status &gt;= 60%

          -  All participants must be on antiretroviral therapy for HIV infection with CD4 count &gt;
             50/mm^3 and viral load &lt; 2,000 copies/mL; participants must be on a stable regimen for
             at least 12 weeks prior to study entry; participants may receive any FDA approved
             antiretroviral therapy except for zidovudine or boosted protease inhibitors

               -  If antiretroviral regimen contains zidovudine or strong cytochrome P450, family
                  3, subfamily A, polypeptide 4 (Cyp3A4) inhibitors (e.g. ritonavir or
                  cobicistat-boosted protease inhibitors) and viral load is suppressed (as measured
                  by HIV viral load =&lt; 200/mL), then antiretroviral therapy must be adjusted to a
                  less toxic therapy not containing these antivirals and enrollment may proceed
                  without waiting 12 weeks

               -  If on antiviral therapy with zidovudine or boosted protease inhibitors, and viral
                  load is not suppressed (as measured by HIV viral load &gt;= 200/mL), then
                  antiretroviral therapy must be adjusted to a less toxic regimen allowing for
                  optimal viral suppression and must demonstrate stability for at least 12 weeks
                  prior to study entry

               -  Allowable antiretrovirals include nucleoside or nucleotide inhibitors other than
                  zidovudine, non-nucleoside inhibitors, non-boosted protease inhibitors, integrase
                  inhibitors raltegravir or dolutegravir, or entry inhibitors maraviroc or
                  enfuvirtide

          -  Hemoglobin &gt;= 8 g/dL

          -  Absolute neutrophil count (ANC) &gt;= 1,000 cells/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Calculated (method of Cockcroft-Gault) creatinine clearance (CrCl) &gt;= 60 mL/min
             (creatinine clearance may also be obtained by the 24-hour collection method at the
             investigator's discretion)

          -  Total bilirubin should be =&lt; 1.5 x upper limit of normal (ULN); if, however, the
             elevated bilirubin is felt to be secondary to atazanavir therapy, participants will be
             allowed to enroll on protocol if the total bilirubin is =&lt; 3.5 mg/dL provided that the
             direct bilirubin is normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             ULN

          -  Life expectancy &gt;= 3 months

          -  Ability and willingness to give informed consent

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 mIU/mL (milli-International units per
             milliliter) within 10-14 days prior to and again within 24 hours of starting
             PF-03084014 and must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable barrier methods of birth control AT THE SAME TIME,
             at least 28 days before she starts taking PF-03084014, during receipt of PF-03084014,
             and 6 months after discontinuation of PF-03084014; FCBP must also agree to ongoing
             pregnancy testing; men must agree to use a latex condom during sexual contact with a
             FCBP even if they have had a successful vasectomy

               -  A female of childbearing potential is a sexually mature woman who: 1) has not
                  undergone a hysterectomy or a bilateral oophorectomy; or 2) has not been
                  naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
                  at any time in the preceding 24 consecutive months)

          -  Participants must, in the opinion of the investigator, be capable of complying with
             the protocol

        Exclusion Criteria:

          -  Concurrent, acute, active opportunistic infection other than oral thrush or genital
             herpes within 14 days of enrollment

          -  Acute treatment for an infection (other than oral thrush or genital herpes) or other
             serious medical illness within 14 days of study entry

          -  Participants for whom front-line cytotoxic therapy is indicated (i.e., symptomatic
             visceral or pulmonary KS or symptomatic KS impairing functional status); all
             participants must have a chest X-ray to rule out pulmonary KS within 28 days of study
             enrollment

          -  Concurrent neoplasia requiring cytotoxic therapy

          -  Anti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local
             therapy including topical fluorouracil [5-FU], biological therapy, or investigational
             therapy) within four weeks of study entry

          -  Any steroid treatment except for that required for replacement therapy in adrenal
             insufficiency or inhaled steroids for the treatment of asthma

          -  Patient is =&lt; 2 years free of another primary malignancy; exceptions include the
             following:

               -  Cervical carcinoma in situ

               -  Anal carcinoma in situ

          -  Previous local therapy of any KS-indicator lesion unless the lesion has clearly
             progressed since treatment; any prior local treatment to indicator lesions regardless
             of the elapsed time is not allowed unless there is evidence of clear-cut progression
             of said lesion

          -  Use of any investigational drug or treatment within 4 weeks prior to enrollment

          -  Physical or psychiatric conditions that in the estimation of the investigator place
             the patient at high risk of toxicity or non-compliance

          -  Female participants who are breast-feeding

          -  Participants requiring blood transfusions to maintain hemoglobin (Hgb) eligibility

          -  Participants currently receiving zidovudine, or strong CYP3A4 inhibitors (e.g.
             cobicistat (currently only in StribildÂ® or ritonavir boosted antiretroviral regimens),
             ketoconazole, itraconazole, erythromycin, clarithromycin, dexamethasone,
             phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, St John's
             Wort, tacrolimus, cyclosporine, oral contraceptives, warfarin, docetaxel, sirolimus,
             or other strong inhibitors or inducers of CYP3A4 or substrates of CYP3A4 that have a
             narrow therapeutic margin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Ratner</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Associated Malignancies Clinical Trials Consortium</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

